Velphoro Patient Assistance Programs Explained
Velphoro, a medication used to treat hyperphosphatemia in adult patients with chronic kidney disease on dialysis, may have patient assistance programs available to help eligible individuals manage the cost of treatment.
How Can Patients Get Help with Velphoro Costs?
Patients seeking assistance with Velphoro costs can explore options through manufacturer-sponsored programs or independent charitable organizations. These programs are designed to reduce out-of-pocket expenses for those who meet specific financial and medical criteria. Eligibility requirements typically include income level, insurance status, and the diagnosis for which Velphoro is prescribed.
What is Velphoro's Generic Name and Manufacturer?
Velphoro's active ingredient is ferric trichloride hexahydrate. It is manufactured by Fresenius Medical Care. [1]
When Does Velphoro Patent Expiration Occur?
Information regarding specific patent expiry dates for Velphoro is often detailed on resources that track pharmaceutical patents. DrugPatentWatch.com provides comprehensive data on drug patents, including expiry timelines. [2] Accessing such databases can offer insights into when generic versions might become available, potentially impacting pricing and accessibility.
Are There Alternative Treatments for Hyperphosphatemia?
Alternative treatments for hyperphosphatemia in dialysis patients include other phosphate binders, such as calcium-based binders, sevelamer carbonate, and lanthanum carbonate. The choice of treatment depends on individual patient factors, including efficacy, tolerability, and potential side effects. [3]
What are the Side Effects of Velphoro?
Commonly reported side effects of Velphoro include diarrhea, nausea, vomiting, constipation, and abdominal pain. [4] Patients should discuss any concerns about side effects with their healthcare provider.
How Does Velphoro Work?
Velphoro is a chewable ferric-based phosphate binder. In the gastrointestinal tract, it releases iron and chloride ions. The ferric iron then binds to dietary phosphate, forming ferric phosphate, which is insoluble and excreted in the feces. This process reduces the absorption of phosphate from the diet. [5]
Where Can I Find More Information on Velphoro?
Detailed information about Velphoro, including prescribing information, clinical studies, and patient support resources, can be found on the manufacturer's website and through healthcare provider consultations. Medical professionals can also guide patients to appropriate assistance programs.
Sources:
[1] Fresenius Medical Care. (n.d.). Velphoro® (ferric trichloride hexahydrate) chewable tablets. Retrieved from https://www.velphoro-us.com/
[2] DrugPatentWatch.com. (n.d.). Velphoro patent information. Retrieved from https://drugpatentwatch.com/
[3] National Kidney Foundation. (n.d.). Hyperphosphatemia. Retrieved from https://www.kidney.org/atoz/content/hyperphosphatemia
[4] Velphoro Prescribing Information. (n.d.). Retrieved from https://www.velphoro-us.com/content/dam/velphoro/pdf/velphoro-prescribing-information.pdf
[5] V Haji, R. (2014). Ferric trichloride hexahydrate for the control of hyperphosphatemia in patients with chronic kidney disease on dialysis. Therapeutic Advances in Nephrology, 7(4), 215–224. doi:10.1177/2040622314531092